ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TVRD vs LSTA // REVENUE GROWTH (YOY)

Tvardi Therapeutics Inc. (NASDAQ) VS. Lisata Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: TVRD 1 — LSTA 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TVRD VS. LSTA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TVRD LSTA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin — -60.00% — TIE /operating-margins <GO>
Net Profit Margin — -60.00% — TIE /net-margins <GO>
Revenue Growth (YoY) ACTIVE — -65.00% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 3/9 -1.00 LSTA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 34.2 38.1 -3.90 LSTA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $11.5M $10.9M $599.4K TVRD /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TVRD REV LSTA REV TVRD GROSS % LSTA GROSS % TVRD FCF LSTA FCF
FY 2025 $0 $170.0K — — -$23.5M -$16.0M
FY 2024 $7.1M $1.0M — — -$19.4M -$19.4M
FY 2023 $21.0M $0 — — -$92.1M -$20.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TVRD // BETA —
LSTA // BETA —